Treatment of Life Threatening Haemorrhage in Infant with Haemangiomatosis and with Manifestations of the Kassabach-Merrit Syndrome by Activated Recombinant Factor VII (rFVIIa)
Authors:
J. Blatný; O. Magnová; J. Štěrba
Authors‘ workplace:
Oddělení dětské onkologie, FN Brno - Dětská nemocnice, primář MUDr. J. Štěrba, PhD.
Published in:
Čes-slov Pediat 2002; (4): 172-173.
Category:
Overview
Recombinant Factor VIIa (rFVIIa) was successfully used to avert life-threatening bleeding in an infant with retroperitoneal haemangiomatosis and Kassabach-Merrit Syndrome. The use of rFVIIa in this patient was life-saving and enabled multimodal treatment of haemangiomatosis with chemotherapy and radiotherapy. This clinical experience thus contributes to the idea of further studies of rFVIIa as a haemostatic agent.
Key words:
Reombinant Factor VIIa, rFVIIa, haemangiomatosis, Kassabach-Merrit Syndrome
Labels
Neonatology Paediatrics General practitioner for children and adolescentsArticle was published in
Czech-Slovak Pediatrics
2002 Issue 4
Most read in this issue
- Brachial Palsy in Neonates
- Acute Toxicity Induced by Iphosphamide in Anticancer Chemotherapy in Children
- Evaluation of the Biological Proportional Age in Overweight Children
- Pathophysiological Mechanisms of Meconium Aspiration Syndrome